Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Argenx (ARGX) to EUR 650 from EUR 715 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Halozyme says Argenx received EU approval for Vyvgart with Enhanze for CIDP
- Argenx announces European Commission approval of VYVGART subcutaneous injection
- Promising Clinical Trial Results and Strategic Pipeline Development Position Argenx Se as a Strong Investment Prospect
- Argenx SE Reports Promising Phase 2 Results for Efgartigimod in Autoimmune Diseases
- Argenx presents new Efgartigimod data at EULAR 2025